"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves osimertinib (Tagrisso) for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC

FDA Approves osimertinib (Tagrisso) for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC

31 Mar 2017 8:43 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to osimertinib (Tagrisso) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software